AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

[1]  S. Digumarthy,et al.  P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status , 2021 .

[2]  N. Shire,et al.  STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world , 2020, PloS one.

[3]  J. Lunceford,et al.  Abstract CT084: Relationship betweenSTK11andKEAP1mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC , 2020, Tumor Biology.

[4]  Hannah L Williams,et al.  Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy , 2020, Cell.

[5]  Lingling Wu,et al.  cGAS-STING–mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy , 2020, Science Translational Medicine.

[6]  J. Shay,et al.  Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. , 2020, Cancer cell.

[7]  R. Flavell,et al.  IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy , 2020, Nature.

[8]  yang-xin fu,et al.  Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling , 2020, Nature Immunology.

[9]  E. Kenigsberg,et al.  A conserved dendritic-cell regulatory program limits antitumour immunity , 2020, Nature.

[10]  H. Ditzel,et al.  AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  S. Berger,et al.  TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. , 2019, Immunity.

[12]  C. Van Waes,et al.  Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells , 2019, Clinical Cancer Research.

[13]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[14]  J. Mazières,et al.  Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  E. Schmidt,et al.  A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. , 2019, Journal of Clinical Oncology.

[16]  J. Riess,et al.  Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. , 2019, Journal of Clinical Oncology.

[17]  Howard Y. Chang,et al.  Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.

[18]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[19]  T. Okazaki,et al.  Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas , 2019, Molecular Cancer.

[20]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[21]  Lai Guan Ng,et al.  Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.

[22]  Arturas Ziemys,et al.  Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues , 2018, The Journal of Immunology.

[23]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[24]  Erik Sundström,et al.  RNA velocity of single cells , 2018, Nature.

[25]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[26]  Boxi Kang,et al.  Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing , 2018, Nature Medicine.

[27]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[28]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[29]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[30]  B. Jiang,et al.  AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling , 2018, Nature Microbiology.

[31]  Yan Li,et al.  Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models , 2017, Oncotarget.

[32]  Hannah A. Pliner,et al.  Reversed graph embedding resolves complex single-cell trajectories , 2017, Nature Methods.

[33]  X. Shirley Liu,et al.  Revisit linear regression-based deconvolution methods for tumor gene expression data , 2017, Genome Biology.

[34]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[35]  J. H. Kim,et al.  Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review , 2017, Oncotarget.

[36]  L. Byers,et al.  Giving AXL the axe: targeting AXL in human malignancy , 2017, British Journal of Cancer.

[37]  I. Wistuba,et al.  Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  H. Stehr,et al.  Reprogramming the immunological microenvironment through radiation and targeting Axl , 2016, Nature Communications.

[39]  Sandra P. Calderon-Copete,et al.  T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. , 2016, Immunity.

[40]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[41]  M. Diamond,et al.  AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity , 2016, eLife.

[42]  Zhichen Sun,et al.  CTLA-4 Limits Anti-CD20–Mediated Tumor Regression , 2016, Clinical Cancer Research.

[43]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[44]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[45]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[46]  P. Través,et al.  Diversification of TAM receptor function , 2014, Nature Immunology.

[47]  Cole Trapnell,et al.  The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells , 2014, Nature Biotechnology.

[48]  R. Weichselbaum,et al.  Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. , 2014, Cancer cell.

[49]  yang-xin fu,et al.  Type I interferon response and innate immune sensing of cancer. , 2013, Trends in immunology.

[50]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[51]  M. Carroll,et al.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3 , 2010, Leukemia.

[52]  Pedro M. Valero-Mora,et al.  ggplot2: Elegant Graphics for Data Analysis , 2010 .

[53]  K. Murphy,et al.  Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells , 2010, The Journal of experimental medicine.

[54]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[55]  R. Paus,et al.  Survival and Migration of Human Dendritic Cells Are Regulated by an IFN-α-Inducible Axl/Gas6 Pathway1 , 2009, The Journal of Immunology.

[56]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[57]  I. Weissman,et al.  In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood , 2008, Nature Protocols.

[58]  M. Meyerson,et al.  Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.

[59]  G. Lemke,et al.  TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.

[60]  G. Lemke,et al.  Macrophages and Dendritic Cells Use Different Axl/Mertk/Tyro3 Receptors in Clearance of Apoptotic Cells1 , 2007, The Journal of Immunology.

[61]  David Carling,et al.  Supplemental Data LKB 1 Is the Upstream Kinase in the AMP-Activated Protein Kinase Cascade , 2003 .

[62]  H. Yamane,et al.  Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 , 1995, Nature.

[63]  R. Shaw,et al.  The AMPK-related kinases SIK1 and SIK3 mediate key tumor suppressive effects of LKB1 in NSCLC. , 2019, Cancer discovery.

[64]  A. Maitra,et al.  Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. , 2018, Cancer research.

[65]  Sebastian Amigorena,et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. , 2014, Cancer cell.

[66]  R. Paus,et al.  Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible AXL/GAS6 pathway , 2009 .

[67]  Dr Ferdiye Taner,et al.  The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.